UK markets closed
  • NIKKEI 225

    27,820.40
    +42.50 (+0.15%)
     
  • HANG SENG

    19,518.29
    +842.94 (+4.51%)
     
  • CRUDE OIL

    78.07
    -1.91 (-2.39%)
     
  • GOLD FUTURES

    1,781.80
    -27.80 (-1.54%)
     
  • DOW

    34,011.59
    -418.29 (-1.21%)
     
  • BTC-GBP

    14,009.19
    -68.26 (-0.48%)
     
  • CMC Crypto 200

    403.38
    -7.83 (-1.90%)
     
  • ^IXIC

    11,261.00
    -200.50 (-1.75%)
     
  • ^FTAS

    4,143.21
    +4.40 (+0.11%)
     

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

So should Kura Oncology (NASDAQ:KURA) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for Kura Oncology

How Long Is Kura Oncology's Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Kura Oncology last reported its balance sheet in September 2021, it had zero debt and cash worth US$543m. Importantly, its cash burn was US$101m over the trailing twelve months. So it had a cash runway of about 5.4 years from September 2021. Importantly, though, analysts think that Kura Oncology will reach cashflow breakeven before then. If that happens, then the length of its cash runway, today, would become a moot point. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Kura Oncology's Cash Burn Changing Over Time?

Kura Oncology didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 50% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can Kura Oncology Raise More Cash Easily?

While Kura Oncology does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Kura Oncology has a market capitalisation of US$842m and burnt through US$101m last year, which is 12% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

So, Should We Worry About Kura Oncology's Cash Burn?

As you can probably tell by now, we're not too worried about Kura Oncology's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. One real positive is that analysts are forecasting that the company will reach breakeven. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for Kura Oncology (1 is concerning!) that you should be aware of before investing here.

Of course Kura Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.